

Collaborative Working Project executive summary

| | |
|-------------------------------|--|
| Project title | Collaborative working project between Cardiff and Vale University Health board and Sanofi to support the development of improved severe asthma services |
| Partner organisation/s | Cardiff and Vale University Health Board, University Hospital Llandough, University Hospital of Wales, Cardiff CF64 2XX Sanofi 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT |
| Project rationale | <p>The overall aim of the Cardiff and Vale University health board respiratory department working in partnership with Sanofi is to support a dedicated pathway facilitator role in undertaking a review of the severe asthma pathways within C&V UHB hospitals.</p> <p>They will focus on identification of the gaps and issues with the ‘front door’ management of severe asthma patients, follow-up after A&E attendance/ hospital admission and put in place systems and make recommendations to address the issues. It will also review the referral pathways for severe asthma patients from the primary referral sites into the severe asthma centre.</p> <p>In addition, this role will serve as a Biologics Nurse, expanding current biologics clinics to support the reduction in backlog in addition to SST testing for the department.</p> <p>A key outcome of the project will be to develop a business case (SBAR) to ensure that the proposed pathway changes are implemented and sustained and to make the business case for the continuation of additional biologics nurse capacity. This will ensure that the outcomes from the project are sustained in the longer term.</p> |
| Project period | Quarter 1 2023 and will conclude in quarter 4 2023 |
| Project objectives | <p>Patients:</p> <ul style="list-style-type: none"> • Continuation in access to biologic medication for the treatment of severe asthma • reduction in the waiting times to access services • Improvements in the patient pathway to ensure that patients attending A&E or being admitted through |

| | |
|-------------------------------|--|
| | <p>hospital are appropriately followed up to optimise their treatment post exacerbation</p> <ul style="list-style-type: none"> • Improvement in patient experience <p>NHS :</p> <ul style="list-style-type: none"> • Increased HCP capacity • Reduction in backlog/ wait times • Supporting in achieving the Respiratory medicine post covid recovery goals • Potential reduction in associated hospitalisations due to impact of worsening disease • Improved patient pathway for both Front door access to severe asthma service and referral site access to severe asthma service • Production of business case (SBAR) to sustain the pathway improvements in the longer term <p>Sanofi:</p> <ul style="list-style-type: none"> • A better understanding of the Severe asthma service and pathway across the Cardiff and Vale • Greater understanding of the needs of the customer in Severe asthma • Improved reputation within Cardiff and Vale UHB • As Sanofi produce medicines within this disease area if overall patient care is optimised there may be an increase in the usage of these products in line with local guidelines • |
| <p>Contact details</p> | <p>Fleur Chandler Director of Patient Access UK & Ireland, GB-marketaccess@sanofi.com</p> <p>Emma Keen Deputy General Manager – Integrated Medicine tel. 0292074 7747</p> |